Background: Most colorectal liver metastases (CRLM) are not candidates for liver resection. Radiofrequency ablation (RFA) plays a key role in selected CRLM patients. Neoadjuvant chemotherapy (NAC) followed by liver resection has been widely used for resectable CRLM. Whether NAC followed by radiofrequency ablation (RFA) can achieve a similar prognosis to NAC followed by hepatectomy remains is unclear. The present study aimed to provide a new treatment modality for CRLM patients. Methods: This comparative retrospective research selected CRLM patients from 2009 to 2022. They were divided into NAC + RFA group and NAC + hepatectomy group. The propensity score matching (PSM) was used to reduce bias. We used multivariate cox proportional hazards regression analysis to explore independent factors affecting prognosis. The primary study endpoint was the difference in the progression-free survival (PFS) between the two groups. Results: A total of 190 locally curable CRLM patients were in line with the inclusion criteria. A slight bias was detected in the comparison of basic clinical characteristics between the two groups. RFA showed a significant advantage in the length of hospital stay (median; 2 days vs. 7 days; p < 0.001). The 1- and 3-year PFS in the liver resection and the RFA groups was 57.4% vs. 86.9% (p < 0.001) and 38.8% vs. 55.3% (p = 0.035), respectively. The 1-year and 3-year OS in the liver resection and RFA groups was 100% vs. 96.7% (p = 0.191) and 73.8% vs. 73.6% (p = 0.660), respectively. Conclusions: NAC followed by RFA has rapid postoperative recovery, fewer complications, and better prognosis.

Neoadjuvant chemotherapy for patients with colorectal liver metastasis often results in varying outcomes. This study aimed to develop a clinical prediction model incorporating the C-reactive protein-to-albumin ratio to determine neoadjuvant chemotherapy efficacy in patients with colorectal liver metastasis METHODS: This retrospective study included 1,335 patients with colorectal liver metastasis who received neoadjuvant chemotherapy. Patients were classified into high and low C-reactive protein-to-albumin ratio groups on the basis of an optimal cutoff value. Multivariate regression and Cox proportional hazards models were used to examine associations between clinical factors and progression-free survival. A prediction model was constructed and validated both internally and externally. The optimal C-reactive protein-to-albumin ratio cutoff value was 0.234. Patients with a high C-reactive protein-to-albumin ratio had a greater risk of 3-year disease progression and shorter 5-year survival (both P < .05). The final model incorporated C-reactive protein-to-albumin ratio value, clinical risk score, and tumor differentiation. It demonstrated excellent performance in predicting progression-free survival (C-index = 0.69) and OS (C-index = 0.72), outperforming the clinical risk score alone in both internal and external validations. The C-reactive protein-to-albumin ratio is an effective independent predictor for patients with colorectal liver metastasis receiving neoadjuvant chemotherapy. The clinical prediction model exhibited superior predictive ability, potentially improving individualized treatment decisions patients with colorectal liver metastasis.

Aberrations in fibroblast growth factor receptors (FGFRs) constitute a key oncogenic mechanism across multiple solid tumors, influencing tumor initiation, therapeutic response, and clinical outcomes. This review synthesizes current knowledge on the molecular biology, signaling networks, and tumor-specific distribution of FGFR alterations, including amplifications, point mutations, and gene fusions. The mechanistic basis of FGFR-driven tumor progression is discussed, including activation of downstream signaling pathways, crosstalk with other receptor tyrosine kinases, and regulation of the tumor microenvironment, angiogenesis, and immune escape. Recent development of selective FGFR inhibitors—such as pemigatinib, erdafitinib, and futibatinib—has translated mechanistic insights into measurable clinical benefits in genomically defined patient populations. However, acquired resistance remains a major challenge, driven by secondary mutations, activation of bypass pathways, and intratumoral heterogeneity. Integration of multi-omics profiling, liquid biopsy monitoring, and biomarker-guided patient selection is essential to optimize therapeutic efficacy and overcome resistance. This review also highlights emerging therapeutic modalities, such as antibody–drug conjugates and nanotechnology-based delivery systems, which may improve target specificity and prolong therapeutic durability. By integrating molecular, translational, and clinical evidence, this review aims to establish a comprehensive framework for precision oncology strategies targeting FGFR-driven malignancies.